Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on May 03, 2023 10:43am
128 Views
Post# 35427422

Excess Visceral fat's effect on cognition

Excess Visceral fat's effect on cognition

"The scientists found that an increase in the type of fat wrapped around the internal organs—known as visceral fat—is associated with poorer performance in cognitive tests of memory, executive function, processing speed, and attention.

When the scientists conducted a deeper dive into the relationship between body fat and cognition, using statistical analysis of genetic data from global databases, they found that a higher body mass index (BMI) and BMI-adjusted waist-to-hip ratio were also linked to a fall in cognitive performance.

NTU LKCMedicine's Professor John Chambers, senior author of the study and HELIOS study's lead investigator, said, "With dementia expected to afflict 78 million people in 2030, and 139 million people by 2050, understanding and addressing the determinants of cognitive function is a major public health priority."

Scientists find link between excess visceral fat and cognitive performance

<< Previous
Bullboard Posts
Next >>